Stockscreener 앱 받기
56.59
3.90%
2.175
전일 마감가:
$54.42
열려 있는:
$55.24
하루 거래량:
11.82M
Relative Volume:
0.78
시가총액:
$115.21B
수익:
$48.03B
순이익/손실:
$6.05B
주가수익비율:
19.11
EPS:
2.9615
순현금흐름:
$15.30B
1주 성능:
+4.83%
1개월 성능:
+8.43%
6개월 성능:
+21.63%
1년 성능:
-1.04%
1일 변동 폭
$55.23
$56.74
1주일 범위
$52.06
$56.74
52주 변동 폭
$42.52
$63.33
브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile
명칭
Bristol Myers Squibb Co
전화
(609) 252-4621
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
BMY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
56.59 | 110.79B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
1,104.85 | 952.34B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.14 | 493.40B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
233.07 | 395.77B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
141.65 | 272.99B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
108.59 | 270.22B | 63.90B | 19.05B | 13.05B | 7.5596 |
브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-12-12 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 개시 | Piper Sandler | Overweight |
| 2024-12-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-13 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-07-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2024-02-06 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-07-10 | 개시 | SVB Securities | Market Perform |
| 2023-06-28 | 개시 | Daiwa Securities | Outperform |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-01-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 개시 | Credit Suisse | Neutral |
| 2022-10-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-06-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Underweight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-01 | 다운그레이드 | Argus | Buy → Hold |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | 업그레이드 | Truist | Hold → Buy |
| 2020-11-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-11-06 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-10-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-07-28 | 개시 | Raymond James | Outperform |
| 2020-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-06 | 재개 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | Argus | Hold → Buy |
| 2019-11-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-08-14 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2019-05-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 재개 | JP Morgan | Overweight |
| 2019-01-15 | 업그레이드 | Societe Generale | Sell → Buy |
| 2018-10-22 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스
Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs - Benzinga
Bristol-Myers Squibb (BMY) Upgraded to Buy with Raised Price Tar - GuruFocus
Bristol-Myers Squibb stock upgraded to Buy at UBS on promising 2026 catalysts - Investing.com India
Why Bristol Myers (BMY) is Poised to Beat Earnings Estimates Again - Finviz
Bristol-Myers Squibb Earns ENERGY STAR® Partner of the Year Award for Third Consecutive Year - CSRwire
Bristol Myers Squibb Company $BMY Position Decreased by D.A. Davidson & CO. - MarketBeat
Is Bristol Myers Squibb a buy, sell, or hold in 2026? - MSN
Myocardial Infarction Market Is Booming Worldwide 2025-2032 | - openPR.com
The Motley Fool: Dividends and a chance for growth - Dallas News
Bristol Myers Squibb: Deep-Value Pharma Play Or Value Trap As Wall Street Turns Cautious? - AD HOC NEWS
Biological Therapies for Cancer Global Markets Report 2025-2030: Merck, BMS, Roche, AstraZeneca, Joh - PharmiWeb.com
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture? - Benzinga
Biological Therapies for Cancer Global Markets Report 2025-2030: Merck, BMS, Roche, AstraZeneca, Johnson & Johnson, and Novartis Drive Growth Through Pipeline Expansion and Strategic CollaborationsResearchAndMarkets.com - FinancialContent
How to watch Bristol Myers Squibb at a major healthcare conference live - Stock Titan
Bristol Myers Squibb Just Shocked Wall Street: Is BMY the Most Slept-On Stock Right Now? - AD HOC NEWS
List of 25 Acquisitions by Bristol-Myers Squibb (Jan 2026) - Tracxn
Looking Into Bristol-Myers Squibb Co's Recent Short InterestBristol-Myers Squibb (NYSE:BMY) - Benzinga
Ex-Dividend Reminder: Encompass Health, Bristol Myers Squibb and Federal Realty Investment Trust - Nasdaq
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now? - Yahoo Finance
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Bristol-Myers Squibb stock edges higher as Wall Street drifts into year-end — what’s next for BMY - ts2.tech
Goldman Sachs Raises Bristol-Myers (BMY) Target, Keeps Neutral Rating - Finviz
BMY vs AMGN: Which Biotech Stock Is More Resilient Now? - Finviz
Is Bristol Myers Squibb a Buy, Sell, or Hold in 2026? - The Motley Fool
Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever - Finviz
Bristol-Myers Squibb Stock Finds a Floor as Wall Street Bets on a Late-Cycle Rebound - AD HOC NEWS
Diversified Trust Co Has $4.56 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Inside Bristol-Myers Squibb: How a Quiet Pharma Giant Is Re?Architecting the Future of Cancer and Im - AD HOC NEWS
What does Wall Street think about Bristol-Myers Squibb Company (BMY)? - MSN
What Does Wall Street Think About Bristol-Myers Squibb Company (BMY)? - Finviz
10 Best Affordable Healthcare Stocks to Buy Now - Insider Monkey
Bristol-Myers Squibb Stock: Defensive Pharma Giant Tests Investor Patience As Wall Street Turns Sele - AD HOC NEWS
Bristol Myers Squibb stock slips today as year-end trading thins and dividend date nears - ts2.tech
Bristol Myers Squibb (BMY) Stock: Weekend News, Analyst Targets, Dividend Update, and What to Watch Before Monday’s Open - ts2.tech
Bristol-Myers Squibb Charts a New Strategic Course with U.S. Government Pact - AD HOC NEWS
Bristol-Myers Squibb (BMY) Stock: Weekend Market Close, Fresh Institutional Filings, and What to Watch Before Monday’s Open - ts2.tech
Meyer Handelman Co. Sells 52,438 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Trust Co. of Toledo NA OH Increases Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb (BMY) Stock News, Forecasts and Outlook as of Dec. 25, 2025: Breyanzi FDA Win, Eliquis Medicaid Deal, and 2026 Catalysts - ts2.tech
Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever - Finviz
Bristol-Myers Squibb: Contrarian Buy For Dividend Hunters, Despite Mounting Growth Headwinds - Seeking Alpha
Bristol Myers Squibb: A Pharma Giant Trading Like Growth Is OverIt's Not - Seeking Alpha
Bristol Myers lines up many launches for India with 'AI' speed - The Economic Times
Bristol-Myers (BMY) Offers Eliquis Free to Medicaid Patients Under New Pricing Pact - Finviz
Is Bristol Myers Squibb (BMY) Still Undervalued After Its Recent Share Price Rebound? - Yahoo Finance UK
Bristol-Myers Squibb (BMY) Stock News Today: Supreme Court Bid, Drug-Pricing Deals, Dividend Boost, and 2026 Forecasts (Dec. 23, 2025) - ts2.tech
J&J, Bristol Myers Ask High Court to Review US Drug Price Cuts - Bloomberg Law News
Bristol-Myers Squibb Surges Into Year-End: Why BMY Still Looks Undervalued (NYSE:BMY) - Seeking Alpha
Bristol-Myers Squibb: Still Undervalued And Generating 4.65% Dividend Yield - Seeking Alpha
Bristol-Myers Squibb stock holds Buy rating at Guggenheim amid oHCM competition - Investing.com India
3 Top Value Stocks to Buy and Hold for 2026 - Morningstar
브리스톨 마이어스 스퀴브 (BMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.31%
0.82%
자본화:
|
볼륨(24시간):